Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shanggan Granule is a Traditional Chinese Medicine (TCM) formulation developed by the Institute of Traditional Chinese Medicine and Clinical Medicine at the China Academy of Chinese Medical Sciences. It is primarily indicated for the treatment of influenza and upper respiratory tract infections (URTI), particularly those manifesting as the "Wind-Heat" pattern in TCM diagnostics. The formulation is a complex mixture of herbal extracts, typically including *Lonicera japonica* (Honeysuckle), *Forsythia suspensa*, *Radix Isatidis*, and *Scutellaria baicalensis*. Pharmacologically, Shanggan Granule exhibits broad-spectrum antiviral activity against various influenza strains (such as H1N1 and H3N2) and possesses significant anti-inflammatory and antipyretic properties. It works by inhibiting viral replication and modulating the host's immune response, specifically by reducing the production of pro-inflammatory cytokines and preventing the progression of respiratory symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shanggan Granule.